Table 3.
Clinical response of patients with pediatric solid tumor
| No. | Tumor responsea | Sum of target lesion diametersb (mm), before/after vaccination | No. of vaccinationsc | PFS (mo) | OS (mo) |
|---|---|---|---|---|---|
| 1 | SD | 54.2/56.2 | 33 | 3.71 | >20.86 |
| 2 | PD | 51.0/NA | 1 | 0.26 | >0.26 |
| 3 | SD | 36.6/41.0 | 16 | 3.71 | 6.97 |
| 4 | PD | 137.7/223.1 | 9 | 0.95 | 7.52 |
| 5 | PD | 22.1/38.4 | 10 | 2.10 | >17.35 |
| 6 | SD | 23.2/24.6 | 13 | 2.33 | >17.15 |
| 7 | SD | 29.0/25.0 | 16 | 5.16 | >16.99 |
| 8 | PD | 20.5/47.0 | 5 | 0.95 | >16.30 |
| 9 | PD | 30.6/56.2 | 2 | 0.43 | >15.93 |
| 10 | Maintaining remission | 0.0/0.0 | 33 | >12.91 | >13.83 |
| 11 | PD | 39.1/68.3 | 8 | 0.92 | >11.86 |
| 12 | Maintaining remission | 0.0/0.0 | 31 | 11.07 | >11.40 |
Abbreviations: NA, not available; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; SD, stable disease.
a
Evaluated 8 wk after the first vaccination according to the RECIST guideline assessment. In cases where remission status was sustained after vaccination, tumor response was defined as maintaining remission.
b
Evaluated before and 8 wk after the first vaccination.
c
Total number of injections of NCCV Cocktail‐1.